Connective tissue growth factor (CTGF/CCN2): Diagnostic and prognostic value in acute heart failure

Clinical Research in Cardiology

Volumn 103, Issue 2, 2014, Pages 107-116

  Behnes, Michael ^a   Brueckmann, Martina ^a,c   Lang, Siegfried ^a   Weiß, Christel ^a   Ahmad Nejad, Parviz ^b   Neumaier, Michael ^a   Borggrefe, Martin ^a   Hoffmann, Ursula ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF WITTEN HERDECKE   (Germany)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Acute heart failure; CTGF; Diagnosis; Fibrosis; NT proBNP; Prognosis; Remodeling

Indexed keywords

AGED; AREA UNDER CURVE; BIOLOGICAL MARKERS; CONNECTIVE TISSUE GROWTH FACTOR; FEMALE; GERMANY; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84893854805     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-013-0626-6     Document Type: Article

References (52)

1. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K et al (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33:1787-1847
2. Maisel A, Mueller C, Adams K Jr, Anker SD, Aspromonte N, Cleland JG et al (2008) State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 10:824-839
3. Metra M, Bettari L, Pagani F, Lazzarini V, Lombardi C, Carubelli V et al (2012) Troponin T levels in patients with acute heart failure: clinical and prognostic significance of their detection and release during hospitalisation. Clin Res Cardiol 101:663-672
4. Behnes M, Brueckmann M, Ahmad-Nejad P, Lang S, Wolpert C, Elmas E et al (2009) Diagnostic performance and cost effectiveness of measurements of plasma N-terminal pro brain natriuretic peptide in patients presenting with acute dyspnea or peripheral edema. Int J Cardiol 135:165-174
5. Lok DJ, Lok SI, Bruggink-Andre de la Porte PW, Badings E, Lipsic E, Van Wijngaarden J et al (2013) Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol 102:103-110
6. Neuberger HR, Cacciatore A, Reil JC, Graber S, Schafers HJ, Ukena C et al (2012) Procollagen propeptides: serum markers for atrial fibrosis? Clin Res Cardiol 101:655-661
7. Braunwald E (2008) Biomarkers in heart failure. N Engl J Med 358:2148-2159 (Pubitemid 351679601)
8. Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA (2006) Controversies in ventricular remodelling. Lancet 367:356-367 (Pubitemid 43151469)
9. Towbin JA (2007) Scarring in the heart: a reversible phenomenon? N Engl J Med 357:1767-1768 (Pubitemid 350005165)
10. Sun Y, Weber KT (1998) Cardiac remodelling by fibrous tissue: role of local factors and circulating hormones. Ann Med 30(Suppl 1):3-8 (Pubitemid 28414368)
11. Weber KT (1997) Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation 96:4065-4082
12. Behnes M, Brueckmann M, Lang S, Espeter F, Weiss C, Neumaier M, et al. Diagnostic and prognostic value of osteopontin in patients with acute congestive heart failure. Eur J Heart Fail 2013. [Epub ahead of print]
13. Behnes M, Hoffmann U, Lang S, Weiss C, Ahmad-Nejad P, Neumaier M et al (2011) Transforming growth factor beta 1 (TGF-beta 1) in atrial fibrillation and acute congestive heart failure. Clin Res Cardiol 100:335-342
14. Brown RD, Ambler SK, Mitchell MD, Long CS (2005) The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol 45:657-687 (Pubitemid 40261821)
15. Weber KT (1997) Monitoring tissue repair and fibrosis from a distance. Circulation 96:2488-2492 (Pubitemid 27451332)
16. Brigstock DR (1999) The connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed (CCN) family. Endocr Rev 20:189-206 (Pubitemid 29339590)
17. Brigstock DR (2010) Connective tissue growth factor (CCN2, CTGF) and organ fibrosis: lessons from transgenic animals. J Cell Commun Signal 4:1-4
18. Daniels A, van Bilsen M, Goldschmeding R, van der Vusse GJ, van Nieuwenhoven FA (2009) Connective tissue growth factor and cardiac fibrosis. Acta Physiol (Oxf) 195:321-338
19. de Sousa Chuva, Lopes SM, Feijen A, Korving J, Korchynskyi O, Larsson J, Karlsson S et al (2004) Connective tissue growth factor expression and Smad signaling during mouse heart development and myocardial infarction. Dev Dyn 231:542-550 (Pubitemid 39410888)
20. Friedrichsen S, Heuer H, Christ S, Cuthill D, Bauer K, Raivich G (2005) Gene expression of connective tissue growth factor in adult mouse. Growth Factors 23:43-53 (Pubitemid 41656870)
21. Koitabashi N, Arai M, Kogure S, Niwano K, Watanabe A, Aoki Y et al (2007) Increased connective tissue growth factor relative to brain natriuretic peptide as a determinant of myocardial fibrosis. Hypertension 49:1120-1127 (Pubitemid 351664300)
22. Koitabashi N, Arai M, Niwano K, Watanabe A, Endoh M, Suguta M et al (2008) Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure. Eur J Heart Fail 10:373-379
23. Adam O, Lavall D, Theobald K, Hohl M, Grube M, Ameling S et al (2010) Rac1-induced connective tissue growth factor regulates connexin 43 and N-cadherin expression in atrial fibrillation. J Am Coll Cardiol 55:469-480
24. Behnes M, Lang S, Breithardt OA, Kaden JJ, Haghi D, Ahmad-Nejad P et al. (2008) Association of NT-proBNP with severity of heart valve disease in a medical patient population presenting with acute dyspnea or peripheral edema. J Heart Valve Dis 17:557-565
25. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Drazner MH, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013. [Epub ahead of print]
26. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA et al (2009) Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 10:165-193
27. Hanley JA, McNeil BJ (1983) A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148:839-843 (Pubitemid 13033817)
28. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27:157-172 (discussion 207-12) (Pubitemid 351193639)
29. Cook NR, Ridker PM (2009) Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med 150:795-802
30. Zobel C, Dorpinghaus M, Reuter H, Erdmann E (2012) Mortality in a cardiac intensive care unit. Clin Res Cardiol 101:521-524
31. Edelmann F, Stahrenberg R, Gelbrich G, Durstewitz K, Angermann CE, Dungen HD et al (2011) Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction. Clin Res Cardiol 100:755-764
32. Reed AL, Tanaka A, Sorescu D, Liu H, Jeong EM, Sturdy M et al (2011) Diastolic dysfunction is associated with cardiac fibrosis in the senescence-accelerated mouse. Am J Physiol Heart Circ Physiol 301:H824-H831
33. Lampe B, Hammerstingl C, Schwab JO, Mellert F, Stoffel-Wagner B, Grigull A et al (2012) Adverse effects of permanent atrial fibrillation on heart failure in patients with preserved left ventricular function and chronic right apical pacing for complete heart block. Clin Res Cardiol 101:829-836
34. Ahmed MS, Gravning J, Martinov VN, von Lueder TG, Edvardsen T, Czibik G et al (2011) Mechanisms of novel cardioprotective functions of CCN2/CTGF in myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 300:H1291-H1302
35. Dendooven A, Gerritsen KG, Nguyen TQ, Kok RJ, Goldschmeding R (2011) Connective tissue growth factor (CTGF/CCN2) ELISA: a novel tool for monitoring fibrosis. Biomarkers 16:289-301
36. Matsui Y, Sadoshima J (2004) Rapid upregulation of CTGF in cardiac myocytes by hypertrophic stimuli: implication for cardiac fibrosis and hypertrophy. J Mol Cell Cardiol 37:477-481 (Pubitemid 38953375)
37. Leask A (2010) Getting to the heart of the matter: CCN2 plays a role in cardiomyocyte hypertrophy. J Cell Commun Signal 4:73-74
38. Wang X, McLennan SV, Allen TJ, Tsoutsman T, Semsarian C, Twigg SM (2009) Adverse effects of high glucose and free fatty acid on cardiomyocytes are mediated by connective tissue growth factor. Am J Physiol Cell Physiol 297:C1490-C1500
39. Ahmed MS, von Lueder TG, Oie E, Kjekshus H, Attramadal H (2005) Induction of myocardial connective tissue growth factor in pacing-induced heart failure in pigs. Acta Physiol Scand 184:27-36 (Pubitemid 40646736)
40. Ohnishi H, Oka T, Kusachi S, Nakanishi T, Takeda K, Nakahama M et al (1998) Increased expression of connective tissue growth factor in the infarct zone of experimentally induced myocardial infarction in rats. J Mol Cell Cardiol 30:2411-2422 (Pubitemid 28549991)
41. Kemp TJ, Aggeli IK, Sugden PH, Clerk A (2004) Phenylephrine and endothelin-1 upregulate connective tissue growth factor in neonatal rat cardiac myocytes. J Mol Cell Cardiol 37:603-606 (Pubitemid 38953387)
42. Ruperez M, Lorenzo O, Blanco-Colio LM, Esteban V, Egido J, Ruiz-Ortega M (2003) Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circulation 108:1499-1505 (Pubitemid 37176458)
43. Bohm M, Voors AA, Ketelslegers JM, Schirmer SH, Turgonyi E, Bramlage P et al (2011) Biomarkers: optimizing treatment guidance in heart failure. Clin Res Cardiol 100:973-981
44. Januzzi JL Jr, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG et al (2005) The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95:948-954 (Pubitemid 40487743)
45. Rachfal AW, Brigstock DR (2005) Structural and functional properties of CCN proteins. Vitam Hormone 70:69-103 (Pubitemid 43589023)
46. Arnott JA, Lambi AG, Mundy C, Hendesi H, Pixley RA, Owen TA et al (2011) The role of connective tissue growth factor (CTGF/CCN2) in skeletogenesis. Crit Rev Eukaryot Gene Expr 21:43-69
47. Boor P, Floege J (2011) Chronic kidney disease growth factors in renal fibrosis. Clin Exp Pharmacol Physiol 38:441-450
48. Dhar A, Ray A (2010) The CCN family proteins in carcinogenesis. Exp Oncol 32:2-9
49. Jungel A, Distler JH, Gay S, Distler O (2011) Epigenetic modifications: novel therapeutic strategies for systemic sclerosis? Expert Rev Clin Immunol 7:475-480
50. Li GM, Fan JG (2011) The role of CTGF in mediating hepatocytes epithelial-to-mesenchymal transition and hepatic fibrogenesis. Zhonghua Gan Zang Bing Za Zhi 19:795-797
51. Phanish MK, Winn SK, Dockrell ME (2010) Connective tissue growth factor-(CTGF, CCN2) - a marker, mediator and therapeutic target for renal fibrosis. Nephron Exp Nephrol 114:e83-e92
52. Gerritsen KG, Abrahams AC, Peters HP, Nguyen TQ, Koeners MP, den Hoedt CH et al (2012) Effect of GFR on plasma N-terminal connective tissue growth factor (CTGF) concentrations. Am J Kidney Dis 59:619-627